Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced the presentations of new pre-clinical data on the mechanism of action supporting selective targeting of single point mutations.
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, is reporting initial …
We see Idera’s next generation antisense platform as a driver of future value for the company, says Wedbush
In a research report issued yesterday, Wedbush analyst Heather Behanna reiterated a Buy rating and $6.00 price target on shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA), …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for oncology and rare …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced new preclinical …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that …
Idera Pharmaceuticals Inc (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced several …
